Birkenfeld, June 15, 2010

STRATEC Biomedical Systems AG, Birkenfeld, Germany, (Frankfurt: SBS; Prime Standard) and bioMérieux (NYSE Euronext: BIM) have signed a contract for the development and supply of components for the next generation VIDAS® instrument for in vitro diagnostics.

STRATEC will be responsible for the design and delivery of customized state of the art modules for the new generation of VIDAS®, which will offer the same extensive clinical panel of 91 assays as the current system, including infectious diseases, cardiovascular diseases and cancer for both routine and high value medical testing. The new automated immunoanalyzer is expected to be launched in 2012 in Europe and Asia-Pacific and in the US after 2012.

The installed base of bioMérieux’s VIDAS® is the largest of any laboratory immunoassay platform, with around 26,000 systems operating globally for clinical and industrial applications. With a workload of up to 100 tests per day, VIDAS® offers an economical solution for small to medium sized laboratories and hospitals with a requirement for a user friendly, automated analyzer which delivers results within minutes. These features have also contributed to growing demand for the system in emerging countries such as China.

Hermann Leistner, CEO of STRATEC commented: “We are very pleased to have gained the trust of bioMérieux to develop and deliver crucial components of a new system, the predecessor of which is one of the most used and trusted automated immunoanalyzer systems in the IVD industry worldwide. STRATEC is delighted to contribute its expertise to make the new VIDAS® product line an even greater success. With a launch in 2012 the new project will be an additional contributor to STRATEC’s growth in the medium term, giving us additional confidence beyond our 2010 to 2012 revenue CAGR growth projection of greater than 15%.”

 

About bioMérieux

Advancing Diagnostics to Improve Public Health – A world leader in the field of in vitro diagnostics for over 45 years, bioMérieux is present in more than 150 countries through 39 subsidiaries and a large network of distributors. In 2009, revenues reached Euro 1.223 billion with 85% of sales outside of France.

bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMérieux is listed on the NYSE Euronext Paris market (Symbol: BIM – ISIN: FR0010096479). Other information can be found at www.biomerieux.com.

About STRATEC

STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies. Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange, and are a constituent of the Deutsche Börse TecDAX.

The STRATEC Group consists of the publicly listed parent company STRATEC Biomedical AG and of subsidiaries and second-tier subsidiaries in Germany, the USA, the UK, Switzerland and Romania.

 

Further information can be obtained from:

STRATEC Biomedical AG
André Loy, Investor Relations
Gewerbestr. 37, 75217 Birkenfeld
Germany
Phone: +49 7082 7916 190
Fax: +49 7082 7916 999
Email:ir(at)stratec.com